Status Epilepticus

2
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Verona Pharma
Verona PharmaUK - London
2 programs
1
KetaminePhase 31 trial
KetamineN/A1 trial
Active Trials
NCT05756621Recruiting80Est. Sep 2025
NCT02431663Terminated57Est. Mar 2020
UP
UCB PharmaBelgium - Brussels
1 program
1
levetiracetamPhase 21 trial
Active Trials
NCT00362141Unknown12Est. Apr 2008
Pfizer
PfizerNEW YORK, NY
1 program
LorazepamN/A1 trial
Active Trials
NCT03905798Completed206Est. Nov 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Verona PharmaKetamine
UCB Pharmalevetiracetam
Verona PharmaKetamine
PfizerLorazepam

Clinical Trials (4)

Total enrollment: 355 patients across 4 trials

NCT02431663Verona PharmaKetamine

Ketamine in Refractory Convulsive Status Epilepticus

Start: Apr 2015Est. completion: Mar 202057 patients
Phase 3Terminated
NCT00362141UCB Pharmalevetiracetam

Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus

Start: Oct 2006Est. completion: Apr 200812 patients
Phase 2Unknown
NCT05756621Verona PharmaKetamine

Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest

Start: Jan 2022Est. completion: Sep 202580 patients
N/ARecruiting
NCT03905798PfizerLorazepam

LORA-PITA IV General Investigation

Start: Nov 2019Est. completion: Nov 2023206 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 355 patients
3 companies competing in this space